The Development of Metabolic Syndrome on Individuals Suffering from Substance Use Disorders: A Systematic Review

Read full text
Authors: Matome Michael Sekhotha, Tlou R Senosha, Maanda Ravhutendele
Cited by: 0
References: 82

Abstract

The development of substance use disorder (SUD) is a worldwide. People that suffer from SUD has the potential of manifestation of metabolic syndrome (MetS). Obesity/overeating and the development of SUD share numerous similarities. The development of SUD use can lead to a variety of negative health issues, including manifestation of metabolic syndromes. To study will be to investigate the development of metabolic syndrome in individuals suffering from substance use disorders using existing literature. Data from previously published articles were collected and analysed to illustrate the development of metabolic syndrome of people suffer from the development of SUD. Data was collected using different search strategies applying combinations of various keywords related to the MetS and SUD. According to our research, those with SUD had better lipid profiles and reduced body weight and adiposity. Lower blood glucose levels were linked to opiate use in people with diabetes mellitus. Several authors from different countries showed that there were significant differences between people that suffer from SUD that might cause MetS. These were shown by both odds’ ratio and hazard ratio in different studies. Given that SUD, diabetes mellitus (DM), and hypertension are among the leading causes of the global burden of disease, the comorbid MetS with drug use is important. There is adequate evidence that show that during administration and/or withdrawal from adulterated drug significance modification of in nourishment choice and intake occur, with negative or positive health consequence.

Fields of Study & Subjects

Diabetes Cardiovascular Risks and Lipoproteins Substance Abuse Treatment and Outcomes Alcohol Consumption and Health Effects

Publication details

Journal / source
IntechOpen eBooks
Publication date
12 January 2026
Language
EN